



PTO/SB/08a (08-03)

Approved for use through 07/31/2006 GMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

5

Application Number

10/562,852

Filing Date

April 19, 2006

First Named Inventor

Ehud GAZIT

Art Unit

1646 1649

Examiner Name

Not Yet Assigned A DMT

Attorney Docket Number

31230

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cte No.†	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code‡ (If known)			
A	1	US-2002/0086067	04-4-2002	Choi et al.	
	2	US-2002/0151506	10-17-2002	Castillo et al.	
	3	US-2006/0079455	04-13-2006	Gazit et al.	
	4	US-4,331,647	05-25-1982	Goldenberg	
	5	US-4,925,673	05-15-1990	Steiner et al.	
	6	US-5,013,556	07-7-1991	Woodle et al.	
	7	US-5,270,163	12-14-1993	Gold et al.	
	8	US-5,475,096	12-12-1995	Gold et al.	
	9	US-5,567,588	10-22-1996	Gold et al.	
	10	US-5,595,877	01-21-1997	Gold et al.	
	11	US-5,637,459	06-10-1997	Burke et al.	
	12	US-5,643,768	01-1-1997	Kawasaki	
	13	US-5,658,754	08-19-1997	Kawasaki	
	14	US-5,683,867	04-4-1997	Biesecker et al.	
	15	US-5,703,337	06-6-1998	Gold et al.	
	16	US-6,309,669	10-30-2001	Setterstrom et al.	
	17	US-6,326,174	04-4-2001	Joyce et al.	
	18	US-6,610,478	08-26-2003	Takle et al.	
	19	US-6,617,114	09-9-2003	Fowlkes et al.	
	20	US-6,677,153	01-13-2004	Iversen	
	21	US-2006/0079454	04-13-2006	Reches et al.	
	22	US-2006/0194777	08-31-2006	Gazit et al.	
	23	US-6,359,112	03-19-2002	Kapurnioto et al.	
	24	US-4,036,945	07-19-1977	Haber	
	25	US-4,816,567	03-28-1989	Cabilly et al.	
	26	US-4,946,778	07-7-1990	Ladner et al.	
	27	US-5,545,806	08-13-1996	Lonberg et al	
	28	US-5,545,807	08-13-1996	Surani et al.	
	29	US-5,569,825	10-29-1996	Lonberg et al.	
	30	US-5,625,126	04-29-1997	Lonberg et al.	
	31	US-5,633,425	05-27-1997	Lonberg et al.	
	32	US-5,661,016	08-26-1997	Lonberg et al.	
	33	US-6,251,625	07-26-2001	Bommarius et al.	
	34	US-6,255,286	03-3-2001	Yanai et al.	
	35	US-4,626,540	02-2-1986	Capps et al.	
	36	US-2003/0225155	04-4-2003	Fernandez-Pol et al.	
	37	US-4,970,233	11-13-1990	McHugh	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 603. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST).

\* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>2</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>3</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/AMFTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

*Complete if Known*

Application Number	10/562,852
Filing Date	April 19, 2006
First Named Inventor	Ehud GAZIT
Art Unit	4646 1649
Examiner Name	Not Yet Assigned <i>ADatt</i>

Sheet

2

of

5

Attorney Docket Number

31230

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.†	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code‡ (if known)			
<i>AD</i>	38	US-6,593,339	07-15-2003	Eek et al.	
	39	US-5,659,041	08-19-1997	Pollak et al.	
	40	US-2001/041732	11-15-2001	Gurley et al.	
	41	US-2004/029830	02-12-2004	Herbert	
	42	US-2004/152672	05-5-2004	Carson et al.	
	43	US-3,042,685	03-3-1962	Roussel	
	44	US-2,920,080	05-5-1965	Bucourt et al	
	45	US-3,625,973	07-7-1971	Julia	
	46	US-3,790,596	05-5-1974	Shkilikova et al	
	47	US-3,976,639	08-24-1976	Batcho et al.	

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.†	Foreign Patent Documents	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
		Country Code* Number* Kind Code* (if known)				
<i>AD</i>	43	PCT WO 02/094857	11-28-2002	Gutheil et al.		
	49	EP 966,975	07-7-2005	Kohno et al.		
	50	PCT WO 2006/006172	01-19-2006	Gazit et al.		
	51	PCT WO 01/45726	06-28-2001	Schmitz		
	52	JP 02-295923	06-6-1990	Taiyo		
	53	JP 59-044313	03-12-1984	Kimura		
	54	PCT WO 03/077866	09-25-2003	Ash et al.		
	55	JP 60-040061	02-2-1985	Unitika		
	56	PCT WO 97/16191	09-9-1997	Hays et al.		
	57	PCT WO 98/20135	05-14-1998	Fitzgerald et al.		
	58	JP 2000-193661	07-14-2000	Tokyo Rikakikai		
	59	JP 63-044895	02-25-1988	Kyowa Hakko Kogyo		
	60	PCT WO 2006/027780	03-16-2006	Reches et al.		
	61	PCT WO 2006/013552	09-9-2006	Gazit et al.		
	62	PCT WO 2006/018850	02-23-2006	Gazit et al.		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. \*Applicant's unique citation designation number (if known). †See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. ‡Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3).

\* For Japanese patent documents, the indication of the year of this reign of the Emperor must precede the serial number of the patent document. † Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. \*Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitution Form 1445A/RTO

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

She

3

69

**Complete if Known**

Complete if Known	
Application Number	10/562,852
Filing Date	April 19, 2006
First Named Inventor	Ehud GAZIT
Art Unit	1646 1649
Examiner Name	Not Yet Assigned ✓ D. H.
Attorney, Agent or Law Firm Name	

---

**FOREIGN PATENT DOCUMENTS**

---

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.*	Foreign Patent Documents	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
AB	63	PCT WO 2005/027901	03-31-2005	Gazit et al.	
	64	PCT WO 03/039540	05-15-2003	Heefner et al.	
	65	PCT WO 03/070269	08-28-2003	Schraermeyer	
	66	EP 0421946	04-10-1991	Politi et al	
	67	PCT WO 99/42102	08-26-1999	Pappolla	
	68	PCT WO 03/024443	03-27-2003	Martynyuk et al	
	69	PCT WO 00/24390	04-4-2000	Reiner et al.	
	70	PCT WO 2005/016339	02-24-2005	Landreth et al	
	71	PCT WO 2005/085867	09-15-2005	Taniguchi et al.	
✓	72	PCT WO 2006/020681	02-23-2006	Banerjee	
Examiner Initials	A. D. S. - Aditi - Dus			Date Entered	11/21/08

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See *Handbook of Patent Practice*, 14.02, section 10. <sup>3</sup> States the unique designation number assigned by the Office. <sup>4</sup> See 37 CFR 1.136(d).

\* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.<sup>3</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.<sup>4</sup> Applicant is to place a check mark here if English language

Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Collection of information is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including time for reviewing and submitting the completed application to the USPTO. The amount of time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

JAN 03 2007

PTO/SB/08b (08-03)

Approved for use through 06/30/2006 OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Completer if Known

Application Number	10/562,852
Filing Date	April 19, 2006
First Named Inventor	Ehud GAZIT
Group Art Unit	1646 1649
Examiner Name	Not Yet Assigned A. D. GALT

Sheet	4	of	5	Attorney Docket Number
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
A9	73	Appukkuttan et al. "Microwave Enhanced Formation of Electron Rich Arylboronates", Synlett, 8: 1204-1206, 2003. Figs. Scheme 4, Compounds 5A, 5B, 5C, 5D.		
	74	Beugelmans Database Crossfire Beilstein [Online], Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE, Database Accession No. 116671 (BRN) Compounds INDOL-2-YL-Methanol & Beugelmans R.: Bulletin de la Socit? Chimique Fran?aise, P.335-336, 1969.		
	75	Cohen et al "Inhibition of Amyloid Fibril Formation and Cytotoxicity by Hydroxyindole Derivatives", Biochemistry, 45: 4727-4735, 2006. Abstract, P.4728, Col.1, Last §, P.4728, Col.2, § 2, Fig.1, P.4729, Col.1, P.4728, Col.1, Last §, P.4728, Col.2, § 2, Fig.1, P.4728, Col.1, Last §, P.4728, Col.2, § 2, Fig.1, 4, P.4732, Col.2, § 2,3, P.4733, Col.2, § 4.		
	76	Altland et al. "Potential Treatment of Transthyretin-Type Amyloidoses by Sulfite", Neurogenetics, 2: 183-188, 1999.		
	77	Azriel et al "Analysis of the Minimal Amyloid-Forming Fragment of the Islet Amyloid Polypeptide", The Journal of Biological Chemistry, 276(36): 34156-34161, 2001.		
	78	Kimura et al. "Analysis and Prediction of Absorption Profile Including Hepatic First-Pass Metabolism of N-Methyltryptamine, A Potent Stimulant of Gastrin Release Present in Beer, After Oral Ingestion in Rats by Gastrointestinal-Transit-Absorption Model", Drug Metabolism and Disposition, 28(5): 577-581, 2000.		
	79	Higaki et al. "Regulation of Drug Absorption From Small Intestine by Enteric Nervous System I: A Poorly Absorbable Drug Via Passive Diffusion", Drug Metabolism and Pharmacokinetics, 19(3): 198-205, 2004.		
	80	Kisilevsky et al. "Arresting Amyloidosis In Vivo Using Small-Molecule Anionic Sulphonates or Sulphates: Implications for Alzheimer's Disease", Nature Medicine, 1: 143-148, 1995. Abstract.		
	81	Kocisko et al. "New Inhibitors of Scrapie-Associated Prion Protein Formation in A Library of 2,000 Drugs and Natural Products", Journal of Virology, 77(19): 10288-10294, 2003.		
	82	Lashuel et al. "New Class of Inhibitors of Amyloid-? Fibril Formation. Implications for the Mechanism of Pathogenesis in Alzheimer's Disease", The Journal of Biological Chemistry, 277(45): 42881-42890, 2002.		
	83	Oza et al. "Synthesis and Evaluation of Anthranilic Acid-Based Transthyretin Amyloid Fibril Inhibitors", Bioorganic & Medicinal Chemistry Letters, 9: 1-6, 1999.		
	84	Peterson et al. "Inhibiting Transthyretin Conformational Changes That Lead to Amyloid Fibril Formation", Proc. Natl. Acad. Sci. USA, 95: 12956-12960, 1998.		
	85	Westwater et al. "Use of Genetically Engineered Phage to Deliver Antimicrobial Agents to Bacteria: An Alternative Therapy for Treatment of Bacterial Infections", Antimicrobial Agents and Chemotherapy, 47 (4): 1301-1307, 2003.		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.68. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including updating the application. Response to this form is required. The burden estimate does not include the time for the applicant to review the documents on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

JAN 08 2007

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449A/1449B  
U.S. Patent and Trademark OfficeINFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/562,852
Filing Date	April 19, 2006
First Named Inventor	Ehud GAZIT
Group Art Unit	1646 1645
Examiner Name	Not Yet Assigned Adu-H

Sheet	5	of	5	Attorney Docket Number	31230
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
AD	86	Gazit "A Possible Role for 'Phi'-Stacking in the Self-Assembly of Amyloid Fibrils", The FASEB Journal, 16: 77-83, 2002.			
	87	Soto et al. Beta-Sheet Breaker Peptides Inhibit Fibrillogenesis in A Rat Brain Model of Amyloidosis: Implications for Alzheimer's Therapy", Nature Medicine, 4(7): 822-826, 1998.			
	88	Inglot "Comparison of the Antiviral Activity In Vitro of Some Non-Steroidal Anti-Inflammatory Drugs", Journal of General Virology, 4(2): 203-214, 1969.			
	89	Pavia et al. "Antimicrobial Activity of Nicotine Against A Spectrum of Bacterial and Fungal Pathogens", Journal of Medical Microbiology, 49(7): 675-676, 2000.			
	90	Nakajima "Amino Precursor Therapy: Manipulation of Brain Amino Activity With Precursor Amino Acid", Psychiatry and Clinical Neurosciences, 51(5), 267-274, 1997. P.269, Col.1, § 2, 3.			
	91	Lee et al. "Anti-Diabetic Constituent From the Node of Lotus Rhizome (Nelumbo Nucifera Gaertn)", Natural Product Sciences, 7(4), 107-109, 2001. P.108, Col.1, Last § - Col.2, § 1.			
	92	Honma et al. "Use of A Thromboxane A2 Antagonist or Synthase Inhibitor for Treating Central Nervous System Diseases, e.g. Alzheimer Type Dementia." Database WPI, Section Ch. Week 200039, Derwent Publications, Class B05, AN 2000-451668, & WO 00/30683 (Yagami et al.), 2 June 2000. Abstract.			
	93	Losert et al. "Effect of Indole 3 Alkanecarboxylic Acids on Glucose Utilization in Rats" Arzneimittel-Forschung/Drug Research, 25(6): 880-887, 1975. P.880, Col.1, § 6, P.886, Col.2, § 4, 5, P.887, Col.1, § 3.			
	94	Kiselev "Pharmaceutical Composition for Prophylaxis and Treatment of Uterus Cervix Dysplasia and Cancer and Larynx Papillomatosis and Methods of Prophylaxis and Treatment of Said Sickneses Based on Thereof", Database WPI, Section Ch, Week 200328, Derwent Publications, Class B02, AN 2003-286683 & RU 2196568 Cl (Kiselev) 20 Jan. 2003. Abstract.			
	95	Kon-Ya et al "Indole Derivatives as Potent Inhibitors of Larval Settlement by the Barnacle, Balanus Amphitrite", Bioscience Biotechnology Biochemistry, JP, 58(12): 2178-2181, 1994. Compound 102.			

Signature	<i>Adi Duff Adi L Duff</i>	Considered	11/21/06
-----------	----------------------------	------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to be (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and any suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.